Recruiting
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM - NDS-MM-004
Atualizado: 24 março, 2021 | ClinicalTrials.gov
Fase
Gênero(s)
Faixa etária
Localização(ões)
Recruiting
Inclusion Criteria: - Patient is ≥ 18 years old with a diagnosis of Multiple Myeloma - Patient must reside in the USA. - Patients within each of the following subgroups, at one of the following timepoints, will be eligible for entry: 1. Newly-diagnosed multiple myeloma transplant-eligible 2. Patients undergoing their first ASCT 3. Newly-diagnosed multiple myeloma transplant-ineligible 4. Relapsed and/or refractory. Exclusion Criteria: - Patient has a condition(s) that, in the opinion of the Investigator, would make participation infeasible such as inability to provide informed consent, illiteracy, or inability to speak, read, and write in English. - Patient is on hospice. - Patient is receiving or has received an investigational agent < 28 days prior to randomization or during this pilot study.
É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas
